(Q38076953)

28 August 2017

1 reference

title

Hemophilia clinical gene therapy: brief review (English)

1 reference

28 August 2017

0 references

0 references

Christopher E Walsh

1

1 reference

28 August 2017

Katherine M Batt

series ordinal

2

1 reference

28 August 2017

publication date

23 January 2013

1 reference

28 August 2017

published in

Translational Research

1 reference

28 August 2017

volume

161

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

307-312

1 reference

The diagnosis and management of congenital hemophilia

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Clinical progress in gene therapy: sustained partial correction of the bleeding disorder in patients suffering from severe hemophilia B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Prophylaxis in the haemophilia population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

The hope and reality of long-acting hemophilia products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

The carboxyl-terminal region of factor IX is essential for its secretion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Platelets as delivery systems for disease treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Use of blood outgrowth endothelial cells for gene therapy for hemophilia A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Endothelial progenitor cell-based therapy for hemophilia A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Virus treatment questioned after gene therapy death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

New recombinant serotypes of AAV vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Self-complementary AAV vectors; advances and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

X-linked thrombophilia with a mutant factor IX (factor IX Padua).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Quantitative analysis of the packaging capacity of recombinant adeno-associated virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Risk of inhibitor development in mild haemophilia A increases with age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Spliceosome-mediated RNA trans-splicing as a tool for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

RNA repair using spliceosome-mediated RNA trans-splicing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Unique strategies for therapeutic gene transfer in haemophilia A and haemophilia BWFH State-of-the-Art Session on Therapeutic Gene Transfer Buenos Aires, Argentina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.016

10.1016/J.TRSL.2012.12.016

7 January 2021

Identifiers

DOI

1 reference

28 August 2017

1 reference